While often seen as a gift, high intelligence can come with its own unique set of challenges, particularly when navigating a ...

Lecanemab received traditional approval in the U.S. in July 2023 for the treatment of early Alzheimer's disease (AD). This retrospective study was conducted to investigate the actual state of ...

Eisai (ESALF) and Eli Lilly (LLY) post new long-term data for thier Alzheimer's drugs Leqembi and Kisunla, respectively. Read more here.

"Cognition Therapeutics’ drug shows 129% cognitive decline arrest in mild Alzheimer’s" was originally created and published ...

Living through the pandemic aged our brains faster — even among people who never became sick with COVID-19, according to a ...

SaveHealth reports migraines are complex neurological conditions affecting over a billion globally, requiring comprehensive ...

TORONTO -- The antiviral agent valacyclovir demonstrated no benefit in early Alzheimer's disease, the phase II VALAD trial ...

The Alzheimer's Association U.S. Study to Protect Brain Health Through Lifestyle Intervention to Reduce Risk (U.S. POINTER) ...

A structured approach to exercise, diet, brain training, social engagement and clinical testing yielded greater cognitive ...